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Existing models using adult human neural stem cells have the restricted access.  Human induced pluripotent stem 
cells (hiPSCs) can generate allogeneic or patient-specific neural cells/tissues and even mini-brains to provide 
robust in vitro models for applications in drug discovery, neurological disease modeling, and cell therapy.  Toward 
this goal, the objective of this study is to construct 3-D neural models from hiPSCs through the scalable embryoid 
body-based suspension culture which can generate cortical glutamatergic neurons and motor neurons by tuning 
the sonic hedgehog (SHH) signaling.  The differentiation of human iPSK3 cells was induced using dual inhibition 
of SMAD signaling with LDN193189 and SB431542.  Then the neural tissue patterning was tuned through the 
treatment with cyclopamine (the SHH antagonist) or purmorphamine (the SHH agonist) along with other factors 
and further maturation.  The neural cells were characterized at day 20, day 35, and day 55.  Abundant 
glutamatergic neurons (>60%) was observed with the cyclopamine treatment, while the cells were more enriched 
with motor neurons expressing Islet-1 and HB9 (>40%) with the purmorphamine treatment.  The cells also 
expressed pre- and post-synaptic markers (Synapsin I and PSD95), and generated action potentials in response 
to depolarizing current injections and spontaneous excitatory post-synaptic currents after maturation.  To assess 
the cellular responses, three classes of small molecules/drugs were investigated: (1) N-methyl-D-aspartate to 
induce general neural toxicity; (2) matrix metalloproteinases inhibitors to affect matrix remodeling; (3) amyloid β 
(1-42) oligomers to induce disease-specific neural toxicity.  Differential responses to various treatments were 
observed for different neuronal subtypes.  Overall, this study can provide a transformative approach to establish 





Figure 1 – Characterizations of neural spheres 
derived from human iPSK3 cells. (i) Neural spheres 
derived from iPSK3 cells based on embryoid body 
(EB) formation; (ii) cyclopamine-treated cells (day 
35) and purmorphamine-treated cells (day 35). At 
day 35, cyclopamine-treated cells have more 
cortical glutamatergic (Glut) neurons while 
purmorphamine-treated cells have more motor 
neurons expressing Islet-1 (Ist-1) and HB9.  β-tub III 
indicates β-tubulin III.  Both populations express 
pre-synaptic marker synapsin I (Syn I).  Scale bar: 
100 μm. (iii) Action potentials in response to 
depolarizing current injections and at the end of 
hyperpolarizing current injections (“rebound” action 
potentials) (day 30 cells); (iv) spontaneous 
excitatory post-synaptic currents (day 30 cells).  
